文献速递重症综合管理与镇静镇痛呼吸衰竭与机械通气复苏、休克与脓毒症

全球2019冠状病毒病需入住ICU患者的系统评价与Meta分析

Global Impact of Coronavirus Disease 2019 Infection Requiring Admission to the ICU: A Systematic Review and Meta-analysis.
PubMed 文献 · Chest · 2020-10-15
一句话结论全球17国45项研究汇总显示,入住ICU的重症COVID-19患者住院死亡率为28.1%,超过四分之三发生ARDS,需大量器官支持。

该研究为系统评价与Meta分析,检索Medline、Embase和Cochrane图书馆至2020年8月1日,纳入45项研究共16561例来自17个国家、四大洲的成人确诊COVID-19入住ICU患者。汇总显示平均年龄62.6岁,常见合并症为高血压(49.5%)和糖尿病(26.6%),76.1%发生ARDS,67.7%需有创机械通气,65.9%需血管活性药物,16.9%需肾脏替代治疗,6.4%需ECMO。ICU住院时间10.8天,住院时间19.1天,住院死亡率28.1%(95%CI 23.4-33.0;I²=96%),亚组分析未见显著亚组效应。结论提示重症COVID-19患者需要大量器官支持和延长ICU及住院治疗,全球汇总病死率低于三分之一。

要点

  • 入住ICU的成人重症COVID-19患者汇总住院死亡率为28.1%(95%CI 23.4-33.0;I²=96%),即全球估计低于三分之一。
  • 76.1%的重症患者发生ARDS,67.7%需有创机械通气,65.9%需血管活性药物支持。
  • 肾脏替代治疗使用率16.9%,ECMO使用率6.4%,提示部分患者需高级器官支持。
  • ICU住院时间10.8天(95%CI 9.3-18.4),住院时间19.1天(95%CI 16.3-21.9),提示需延长ICU及住院资源配置。
  • 平均年龄62.6岁,常见合并症为高血压49.5%和糖尿病26.6%。

适用人群与场景

  • 年龄大于18岁、确诊COVID-19并入住ICU的成人患者。

研究设计与关键结果

  • 系统评价与Meta分析,纳入45项研究共16561例患者,来自17个国家、四大洲,检索至2020年8月1日。
  • 汇总平均年龄62.6岁(95%CI 60.4-64.7),高血压49.5%(95%CI 44.9-54.0),糖尿病26.6%(95%CI 22.7-30.8)。
  • ARDS发生率76.1%(95%CI 65.7-85.2),有创机械通气67.7%(95%CI 59.1-75.7),血管活性药物65.9%(95%CI 52.4-78.4)。
  • 肾脏替代治疗16.9%(95%CI 12.1-22.2),ECMO 6.4%(95%CI 4.1-9.1)。
  • ICU住院时间10.8天(95%CI 9.3-18.4),住院时间19.1天(95%CI 16.3-21.9),住院死亡率28.1%(95%CI 23.4-33.0;I²=96%)。
  • 亚组分析(地理分布、研究类型、质量评价、样本量、截止日期、患者去向)未见显著亚组效应。

证据类型、等级与局限

  • 证据类型:系统评价与Meta分析,纳入非随机研究,采用纽卡斯尔-渥太华量表进行质量评价。
  • 异质性:住院死亡率汇总分析I²=96%。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 原文结论提示,入住ICU的重症COVID-19患者需要大量器官支持和延长的ICU及住院治疗,全球汇总病死率低于三分之一。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: The coronavirus disease 2019 (COVID-19) pandemic has placed unprecedented burden on the delivery of intensive care services worldwide.

RESEARCH QUESTION: What is the global point estimate of deaths and risk factors for patients who are admitted to ICUs with severe COVID-19?

STUDY DESIGN AND METHODS: In this systematic review and meta-analysis Medline, Embase, and the Cochrane library were searched up to August 1, 2020. Pooled prevalence of participant characteristics, clinical features, and outcome data was calculated with the use of random effects models. Subgroup analyses were based on geographic distribution, study type, quality assessment, sample size, end date, and patient disposition. Studies that reported in-hospital mortality rate of adult patients (age >18 years) with confirmed COVID-19 admitted to an ICU met study eligibility criteria. Critical evaluation was performed with the Newcastle Ottawa Scale for nonrandomized studies.

RESULTS: Forty-five studies with 16,561 patients from 17 countries across four continents were included. Patients with COVID-19 who were admitted to ICUs had a mean age of 62.6 years (95% CI, 60.4-64.7). Common comorbidities included hypertension (49.5%; 95% CI, 44.9-54.0) and diabetes mellitus (26.6%; 95% CI, 22.7-30.8). More than three-quarters of cases experienced the development of ARDS (76.1%; 95% CI, 65.7-85.2). Invasive mechanical ventilation was required in 67.7% (95% CI, 59.1-75.7) of case, vasopressor support in 65.9% (95% CI, 52.4-78.4) of cases, renal replacement therapy in 16.9% (95% CI, 12.1-22.2) of cases, and extracorporeal membrane oxygenation in 6.4% (95% CI, 4.1-9.1) of cases. The duration of ICU and hospital admission was 10.8 days (95% CI, 9.3-18.4) and 19.1 days (95% CI, 16.3-21.9), respectively, with in-hospital mortality rate of 28.1% (95% CI, 23.4-33.0; I2 = 96%). No significant subgroup effect was observed.

INTERPRETATION: Critically ill patients with COVID-19 who are admitted to the ICU require substantial organ support and prolonged ICU and hospital level care. The pooled estimate of global death from severe COVID-19 is <1 in 3.

来源:Chest,查看原文。版权归原作者所有。

参考来源

  1. Tan E, Song J, Deane AM, et al. Global Impact of Coronavirus Disease 2019 Infection Requiring Admission to the ICU: A Systematic Review and Meta-analysis. Chest. 2020. PMID: 33069725. doi:10.1016/j.chest.2020.10.014

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。